346 related articles for article (PubMed ID: 34393221)
41. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Pheochromocytoma and Paraganglioma.
Fuchs TL; Luxford C; Clarkson A; Sheen A; Sioson L; Elston M; Croxson MS; Dwight T; Benn DE; Tacon L; Field M; Ahadi MS; Chou A; Clifton-Bligh RJ; Gill AJ
Am J Surg Pathol; 2023 Jan; 47(1):25-36. PubMed ID: 35993574
[TBL] [Abstract][Full Text] [Related]
42. [Expression of GPNMB in renal eosinophilic tumors and its value in differential diagnosis].
Wang Y; Hou MY; Fu Y; Meng K; Wu HY; Chen J; Xu YM; Shi J; Fan XS
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):358-363. PubMed ID: 36973196
[No Abstract] [Full Text] [Related]
43. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC.
Gupta S; Swanson AA; Chen YB; Lopez T; Milosevic D; Kipp BR; Leibovich BC; Thompson RH; Herrera-Hernandez L; Cheville JC; Jimenez RE
Hum Pathol; 2019 Sep; 91():114-122. PubMed ID: 31299266
[TBL] [Abstract][Full Text] [Related]
44. [Oncocytic papillary renal cell carcinoma: a clinicopathological analysis of nineteen cases].
Zhang W; Zhang LX; Yang T; Zou YW; Liu XL; Yu WJ; Jiang YX; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2022 Oct; 51(10):981-986. PubMed ID: 36207910
[No Abstract] [Full Text] [Related]
45. Acquired Cystic Disease-associated Renal Cell Carcinoma (ACD-RCC): A Multiinstitutional Study of 40 Cases With Clinical Follow-up.
Przybycin CG; Harper HL; Reynolds JP; Magi-Galluzzi C; Nguyen JK; Wu A; Sangoi AR; Liu PS; Umar S; Mehra R; Zhang X; Cox RM; McKenney JK
Am J Surg Pathol; 2018 Sep; 42(9):1156-1165. PubMed ID: 29851703
[TBL] [Abstract][Full Text] [Related]
46. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Gleeson JP; Nikolovski I; Dinatale R; Zucker M; Knezevic A; Patil S; Ged Y; Kotecha RR; Shapnik N; Murray S; Russo P; Coleman J; Lee CH; Stadler ZK; Hakimi AA; Feldman DR; Motzer RJ; Reznik E; Voss MH; Chen YB; Carlo MI
Clin Cancer Res; 2021 May; 27(10):2910-2919. PubMed ID: 33658299
[TBL] [Abstract][Full Text] [Related]
47. [Clinicopathological features and differential diagnosis of eosionphilic chromophobe renal cell carcinoma].
Zhang W; Song TT; He B; Wang H; Kang EH; Yu WJ; Zhong DC; Jiang YX; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2020 Dec; 49(12):1242-1248. PubMed ID: 33287507
[No Abstract] [Full Text] [Related]
48. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
[TBL] [Abstract][Full Text] [Related]
49. AKR1B10 Is a New Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Zheng L; Zhang X; Pan X; Huang Z; Zhang M; Xian J; Wei Y; Nie L; Zhang M; Gong J; Chen X; Zhou Q; Zeng H; Chen N
Mod Pathol; 2023 Nov; 36(11):100303. PubMed ID: 37580017
[TBL] [Abstract][Full Text] [Related]
50. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
[TBL] [Abstract][Full Text] [Related]
51. Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma.
Liang J; Sun G; Pan X; Zhang M; Shen P; Zhu S; Zhao J; Zheng L; Zhao J; Chen Y; Yin X; Chen J; Hu X; Zeng Y; Chen J; Wang Y; Liu Z; Yao J; Su M; Huang R; Liao B; Wei Q; Li X; Zhou Q; Liu J; Shen Y; Liu Z; Chen N; Zeng H; Zhang X
Genome Med; 2023 May; 15(1):31. PubMed ID: 37131267
[TBL] [Abstract][Full Text] [Related]
52. A Case Report of Aggressive Fumarate Hydrase-deficient Renal Cell Carcinoma With Loss of HLA Antigens.
Miura Y; Motoshima T; Anami T; Takemura K; Kinowaki K; Oka S; Urakami S; Kamba T; Komohara Y
Cancer Diagn Progn; 2023; 3(4):522-527. PubMed ID: 37405222
[TBL] [Abstract][Full Text] [Related]
53. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer.
Williamson SR; Gill AJ; Argani P; Chen YB; Egevad L; Kristiansen G; Grignon DJ; Hes O
Am J Surg Pathol; 2020 Jul; 44(7):e47-e65. PubMed ID: 32251007
[TBL] [Abstract][Full Text] [Related]
54. Characterization of protein S-(2-succino)-cysteine (2SC) succination as a biomarker for fumarate hydratase-deficient renal cell carcinoma.
Mannan R; Wang X; Bawa PS; Chugh S; Chinnaiyan AK; Rangaswamy R; Zhang Y; Cao X; Smith SC; Trpkov K; Williamson SR; Sangoi AR; Mohanty S; McKenney JK; Gupta S; Magi-Galluzzi C; Argani P; Osunkoya AO; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Hum Pathol; 2023 Apr; 134():102-113. PubMed ID: 36581128
[TBL] [Abstract][Full Text] [Related]
55. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
[TBL] [Abstract][Full Text] [Related]
56. Morphology and Immunohistochemistry for 2SC and FH Aid in Detection of Fumarate Hydratase Gene Aberrations in Uterine Leiomyomas From Young Patients.
Joseph NM; Solomon DA; Frizzell N; Rabban JT; Zaloudek C; Garg K
Am J Surg Pathol; 2015 Nov; 39(11):1529-39. PubMed ID: 26457356
[TBL] [Abstract][Full Text] [Related]
57. TFEB Rearranged Renal Cell Carcinoma: Pathological and Molecular Characterization of 10 Cases, with Novel Clinical Implications: A Single Center 10-Year Experience.
Wang AX; Tian T; Liu LB; Yang F; He HY; Zhou LQ
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830782
[TBL] [Abstract][Full Text] [Related]
58. Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study.
Nikolovski I; Carlo MI; Chen YB; Vargas HA
Cancer Imaging; 2021 Feb; 21(1):24. PubMed ID: 33608050
[TBL] [Abstract][Full Text] [Related]
59. Fumarate hydratase-deficient renal cell carcinoma: an oncology care institutional experience.
Kamboj M; Gupta G; Pasricha S; Mehta A; Rawal S; Singh A; Sharma A; Durga G; Bansal D; Diwan H
APMIS; 2024 May; ():. PubMed ID: 38775301
[TBL] [Abstract][Full Text] [Related]
60. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
